APE-Study: Tumor-free Survival After Ablation of Barrett's Mucosa Plus Esomeprazole vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs Placebo for Symptomatic Reflux Control After Successful Ablation of Barrett's Mucosa
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
recurrence-free survival
recurrence-free survival during 3 years of follow-up
3 years
No
Christian Ell, MD PhD
Principal Investigator
HSK Wiesbaden
Germany: Federal Institute for Drugs and Medical Devices
D9612L00088
NCT00546065
August 2006
September 2010
Name | Location |
---|